DOSIS OCTREOTIDE PDF

Sandostatin Injection is available as: sterile 1-mL ampuls in 3 strengths, containing 50, mcg octreotide (as acetate), and sterile 5-mL multi-dose vials in 2. Sep 3, Octreotide Acetate (Sandostatin ®) – Intravenous (IV) Dilution. Octreotide (Sandostatin) is the longer acting synthetic analogue of the naturally In patients with cancer and inoperable bowel obstruction octreotide rapidly.

Author: Dourg Shaktikora
Country: Latvia
Language: English (Spanish)
Genre: Art
Published (Last): 19 May 2007
Pages: 158
PDF File Size: 9.54 Mb
ePub File Size: 14.53 Mb
ISBN: 529-4-97238-145-2
Downloads: 56122
Price: Free* [*Free Regsitration Required]
Uploader: Zulkishicage

One-point-cut colourless, type I glass ampoule containing clear colourless solution. At least 5 days of treatment will be needed to judge the efficacy.

Dilution Octreotide -Sandostatin ® – GlobalRPH

Profuse watery diarrhea due to vasoactive intestinal peptide-secreting tumors VIPomas. Emergency management to stop bleeding and to protect from re-bleeding owing to gastro-oesophageal varices in patients with cirrhosis.

During the treatment of GEP endocrine tumours, there may be rare instances of sudden escape from symptomatic control by Sandostatin, with rapid recurrence of severe symptoms. Back to top Hospira UK Ltd contact details. Continue typing to refine.

Step 2 Remove plastic cap from vial and clean rubber stopper of vial with an alcohol wipe.

Octreotide has no or negligible influence ocgreotide the ability to drive and use machines. The product must be used immediately and any unused drug-product must be discarded.

Sandostatin 50 microgram/1 ml, solution for injection/infusion

Marked fluctuations in blood glucose concentration may possibly be reduced by smaller, more frequently administered doses. Known hypersensitivity to the active substance or to any of the excipients listed in section 6.

Marketing authorisation number s 9. In patients with liver cirrhosis, the half-life of the drug may be increased, necessitating adjustment of the maintenance dosage. Injection site reactions Common: In patients with operable tumours, octreotide may help to restore and maintain normoglycaemia pre-operatively. Intravenous infusion Prior to administration the solution should be inspected visually for changes of colour or solid particles.

Octreotide solutions for injection contain less than 1 mmol 23 mg of sodium per 1 ml of solution i. For the full list of excipients see section 6. Administration of octreotide may result in improvement of doss, particularly of flush and diarrhoea. Glucagonomas Administration of Sandostatin results in most cases in substantial improvement of the necrolytic migratory rash which is characteristic of the condition. The effect of octreotide on the state of mild diabetes mellitus which frequently occurs is not marked and, in general, does not result octreoide a reduction of requirements for insulin or oral hypoglycaemic agents.

  BU407 DATASHEET PDF

Relief of symptoms associated with functional gastro-entero-pancreatic GEP endocrine tumours, e.

Dosing Sandostatin® LAR®

Acromegaly octgeotide to or that cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. Qualitative and quantitative composition 3.

This should be repeated as often as necessary until the prescribed duration of treatment is reached. Sandostatin LAR Depot should be administered by a trained health care provider. In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth and development of metastases has not been determined. Octreotode is not known whether octreotide has an effect on human fertility.

Dose adjustments of insulin and antidiabetic medicinal products may be required when Sandostatin is administered concomitantly see section 4. If the treatment is stopped, symptoms may worsen or recur.

Show table of contents Hide table of contents 1. Mimics the action of naturally occuring somatostatin and decreases the secretion of gastroenterohepatic peptides that may contribute to adverse symptoms in patients with metastatic tumors, VIPomas.

Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.

A limited number of accidental overdoses of Sandostatin in adults and children have been reported. Dose adjustment of medicinal products such as beta blockers, calcium channel blockers, or agents to control fluid and electrolyte balance may be necessary when Octreotide is administered concomitantly see section 4. Shelf-life after first opening: Step 7 After the saturation period, ensure plunger is pushed all the way down in the syringe Keep plunger pressed and shake vial moderately in a horizontal direction for a minimum of 30 seconds so the powder is completely suspended uniform milky suspension.

  COMMUNICATE CAUTIVA CONVINCE PDF

Step 5 Remove cap from syringe and screw syringe onto vial adapter Slowly push plunger all the way down to transfer all the diluent solution in the vial.

Octreotide 100 micrograms/1ml Solution for Injection

Administration of Sandostatin produces a fall in circulating immunoreactive insulin, which may, however, be of short duration about 2 hours. Although measured faecal fat excretion may increase, there is no evidence to date that long-term treatment with octreotide dosia led to nutritional deficiency due to malabsorption.

Octreotide has also been infused in lower concentrations. The initial dosage is usually 50 mcg administered twice or three times daily. The earliest reduction was reported after 14 days of treatment. Injection should be administered by a health care professional immediately after it is mixed.

Since it cannot be excluded that octreotide may have this effect, other drugs mainly metabolised by CYP3A4 and which have a low therapeutic index should therefore be used with caution e. Reporting suspected adverse reactions after authorisation of the medicinal product is important. The adverse events reported were arrhythmia, hypotension, ocfreotide arrest, brain hypoxia, pancreatitis, hepatic steatosis, diarrhoea, weakness, lethargy, weight loss, hepatomegaly, and lactic acidosis. There is a limited amount of data less than pregnancy outcomes from the use of octreotide in pregnant women, and in approximately one third of the cases the pregnancy outcomes are unknown.

Step 8 Turn syringe and vial upside down, slowly pull plunger back, and draw entire contents from vial into syringe Unscrew syringe from vial adapter.